dulaglutide + digoxin

**dulaglutide + digoxin** is a combination of two pharmaceuticals: dulaglutide, a recombinant fusion protein acting as a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used for glycemic control in Type 2 diabetes mellitus, and digoxin, a cardiac glycoside used for the management of various heart conditions (such as atrial fibrillation and heart failure). Dulaglutide acts by stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon secretion, and slowing gastric emptying, thus lowering blood glucose. Digoxin increases myocardial contractility by inhibiting sodium-potassium ATPase, resulting in increased intracellular calcium in cardiac cells. Dulaglutide may delay gastric emptying, which can influence the absorption kinetics of drugs like digoxin, but clinical studies indicate no clinically relevant interaction requiring dose adjustments when both drugs are co-administered. Monitoring is advised for digoxin levels due to its narrow therapeutic window, especially at the initiation of co-treatment with a GLP-1 receptor agonist[1][2][3].

Other names

dulaglutide + digoxin